Gilead Sciences (GILD) Gets a Buy Rating from J.P. Morgan

By Jason Carr

J.P. Morgan analyst Cory Kasimov assigned a Buy rating to Gilead Sciences (GILDResearch Report) on May 2 and set a price target of $87. The company’s shares closed yesterday at $67.69.

According to, Kasimov is a 3-star analyst with an average return of 0.6% and a 41.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $82, a 21.1% upside from current levels. In a report issued on April 23, Raymond James also maintained a Buy rating on the stock with a $86 price target.

See today’s analyst top recommended stocks >>

Gilead Sciences’ market cap is currently $86.24B and has a P/E ratio of 14.92. The company has a Price to Book ratio of 3.90.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. Last month, Kevin Lofton, a Director at GILD bought 13,208 shares for a total of $328,879.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.